Market Access News | pharmaphorum

News

Takeda gets okay in US for rare blood disorder drug

Patients in the US with ultra-rare blood clotting disorder congenital thrombotic thrombocytopenic purpura (cTTP) have an FDA-approved therapy for the first time, after Tak

News

First chikungunya vaccine approved by FDA

Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne dis

News

Takeda bags FDA okay for Fruzaqla in colorectal cancer

The FDA has approved Takeda’s Fruzaqla for a group of patients with relapsed or refractory metastatic colorectal cancer, offering another option for patients who have exha

News

Lilly gets FDA okay for tirzepatide as obesity therapy

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a

News

NICE backs 'artifical pancreas' tech for type 1 diabetics

An independent NICE committee has recommended that thousands of people with type 1 diabetes who can’t control the condition with current glucose monitoring and insulin pum

News

Generic breast cancer drug cleared for prevention in England

Almost 30 years after it was first licensed as a treatment for breast cancer, aromatase inhibitor anastrozole has been cleared for preventive use in women at high risk of

Takeda gets okay in US for rare blood disorder drug

First chikungunya vaccine approved by FDA

Takeda bags FDA okay for Fruzaqla in colorectal cancer

Lilly gets FDA okay for tirzepatide as obesity therapy

NICE backs 'artifical pancreas' tech for type 1 diabetics

Generic breast cancer drug cleared for prevention in England

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks